Trials / Completed
CompletedNCT04223349
A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants
A Phase 1, Open-label Single-dose Crossover, and Double-blind Multiple-dose Parallel Group Study to Characterize the Pharmacokinetics, Safety and Tolerability, and Pharmacodynamics of JNJ-70033093 in Healthy Adult Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 66 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to characterize the pharmacokinetic (PK) of multiple twice-daily doses of JNJ-70033093 in healthy participants and to assess the effects of dosing time and food on the PK of single-dose of JNJ-70033093 in healthy participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-70033093 | JNJ-70033093 capsules will be administered orally . |
| DRUG | Placebo | Matching placebo in capsule will be administered orally. |
Timeline
- Start date
- 2020-01-10
- Primary completion
- 2020-04-08
- Completion
- 2020-04-08
- First posted
- 2020-01-10
- Last updated
- 2025-04-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04223349. Inclusion in this directory is not an endorsement.